1. (Currently Amended) A method for the prediction of response to cancer treatment~~, by the detection of at least 2 markers characterized in that the markers are genes and fragments thereof or genomic nucleic acid sequences that are located on one chromosomal region which is altered in malignant neoplasia~~ comprising:

amplifying a nucleic acid sequence in a sample of a patient and

detecting at least 4 markers in the nucleic acid sequence, wherein the at least 4 markers comprise polynucleotides comprising SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379, SEQ ID NO: 392.

2. (Original) The method of claim 1 wherein the treatment is an antibody treatment, antihormonal treatment, anti-growth factor treatment, taxol based treatment, anthracyclin based treatment and platinum salt based treatment.

3. (Original) The method of claim 1 wherein the treatment includes Herceptin™, trastuzumab or 2C4 antibodies.

4. (Canceled)

5. (Currently Amended) The method of claim 1 ~~or 2~~ wherein the malignant neoplasia is breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer.

6. (Canceled)

7. (Currently Amended) A method for the ~~prediction,~~ diagnosis ~~or prognosis~~ of malignant neoplasia ~~by the detection of~~ said method comprising:

amplifying a nucleic acid sequence in a sample of a patient and

detecting at least four markers in the nucleic acid sequence ~~one marker~~ characterized in that the ~~marker is~~ four markers are selected from:

(a) ~~a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 319 to 389~~ polynucleotides comprising SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379, and SEQ ID NO: 392;

(b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) and encodes a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

(c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (~~c~~ b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

(d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (~~d~~ c)

(e) a purified polypeptide encoded by a polynucleotide or polynucleotide analog sequence specified in (a) to (~~e~~ d)

(f) ~~e~~ purified ~~polypeptide~~ polypeptides encoded by SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379, and SEQ ID NO: 392 ~~comprising at least one of the sequences of SEQ ID NO: 397 - 467~~;

~~Are detected~~.

8. – 9. Canceled

10. (New) A diagnostic kit for detecting markers SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379 and SEQ ID NO: 392, said kit comprising polynucleotides which are complementary to a portion of the coding sequence of SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379 and SEQ ID NO: 392.